Nanoscope Therapeutics Expands Catalent Partnership for Late-Stage Optogenetic Therapy
Event summary
- Nanoscope Therapeutics has expanded its partnership with Catalent to support late-phase clinical development and commercial supply of MCO-010, an optogenetic gene therapy for retinal degenerative diseases.
- Catalent will provide commercial-compliant packaging and distribution for MCO-010, including validation program support for Nanoscope's Biologics License Application (BLA).
- A rolling BLA submission with the FDA is currently underway for MCO-010, which aims to restore vision in patients with advanced retinal degenerative diseases like retinitis pigmentosa and Stargardt disease.
The big picture
This expanded partnership underscores the strategic importance of manufacturing and supply chain readiness as Nanoscope Therapeutics advances its lead gene therapy toward commercialization. The collaboration with Catalent highlights the growing trend of biotech companies leveraging specialized CDMOs to navigate complex regulatory pathways and scale production for global markets.
What we're watching
- Regulatory Progress
- The pace at which the FDA reviews Nanoscope's rolling BLA submission will determine the timeline for MCO-010's potential approval and commercial launch.
- Commercial Readiness
- Whether Catalent can scale its packaging and distribution capabilities to meet global demand for MCO-010 as Nanoscope prepares for late-stage development.
- Market Expansion
- How successful MCO-010's optogenetic approach will be in treating multiple retinal degenerative diseases, including retinitis pigmentosa and Stargardt disease.
Related topics